Since we launched our first IVD test kit in 1966 our products have consistently been recognized by the market for their excellence.
We have carried out a number of successful acquisitions of best-in-class IVD companies over the years (e.g. Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010).
This has further reinforced the know-how in our group and bolstered our capacity to innovate, develop, produce and deliver products of only the highest quality.
Products by diseases and disorders:
News & EventsView all news & upcoming events
INNO-LiPA® HPV Genotyping Extra II now CE marked for use on self-collected first-void urine samples
Fujirebio launches the automated Lumipulse® G AMH assay for accurate assessment of ovarian reserve
Fujirebio expands its INNO-LiPA® CFTR assay portfolio with the launch of INNO-LiPA CFTR Extra
Fujirebio Europe announces the availability of the Lumipulse® G pTau 181 and β-Amyloid 1-40 assays extending its offer of fully automated assays as an aid in the early diagnosis of Alzheimer’s disease
Fujirebio Europe announces CE marking of the Lumipulse® G CK-MB assay, used to aid in the diagnosis of Acute Myocardial Infarction (AMI)
Morphotek®, Inc. Announces an Agreement With Fujirebio Diagnostics, Inc to commercialize the CA125 II Assay as a Companion Diagnostic for Farletuzumab®
Pioneering the future of healthcare
We are part of Miraca Group, a global Japanese healthcare player that favors cross-group R&D synergies and expertise in clinical laboratory testing (SRL), IVD testing solutions (Fujirebio) and other specialized healthcare related activities.
As part of Miraca Group we have the capacity to truly understand the patient needs.
We collaborate closely with clinicians and laboratorians worldwide to develope innovative IVD testing solutions for today and tomorrow.
A global partner of choice
Today, we sell our products in more than 100 countries worldwide.
We have offices in the United States, Latin America, Europe and Asia, and are supported by an international distribution network and leading OEMs.
Our proven commitment to manufacturing quality has earned us a strong reputation with our direct customers, and global partners at leading diagnostic companies.
Interstitial lung diseases (ILDs) represent a large, heterogeneous group of more than 200 different entities, most of which are classified as rare...
Oct 24, 2019
In March 2017 the European Association for the Study of the Liver (EASL) added a new serological marker, HBcrAg (Hepatitis B core-related antigen), to...
Jul 10, 2019